Bank Of New York Mellon Corp Crinetics Pharmaceuticals, Inc. Transaction History

Bank Of New York Mellon Corp

$538 Trillion
Q3 2024

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$15.31 - $21.1 $6.47 Million - $8.92 Million	422,789 New	422,789 $6.79 Billion
Q4 2022 Feb 14, 2023	BUY	$15.49 - $19.05 $5.45 Million - $6.7 Million	351,759 New	351,759 $6.44 Million
Q3 2022 Nov 14, 2022	BUY	$18.11 - $22.37 $185,392 - $229,001	10,237 Added 3.09%	341,482 $6.71 Million
Q2 2022 Aug 15, 2022	BUY	$16.49 - $27.64 $234,289 - $392,709	14,208 Added 4.48%	331,245 $6.18 Million
Q1 2022 May 11, 2022	SELL	$17.15 - $28.31 $93,793 - $154,827	-5,469 Reduced 1.7%	317,037 $6.96 Million
Q4 2021 Feb 11, 2022	BUY	$19.35 - $28.41 $390,115 - $572,774	20,161 Added 6.67%	322,506 $9.16 Million
Q3 2021 Nov 12, 2021	BUY	$16.88 - $25.23 $172,007 - $257,093	10,190 Added 3.49%	302,345 $6.37 Million
Q2 2021 Aug 11, 2021	BUY	$15.9 - $21.15 $88,690 - $117,974	5,578 Added 1.95%	292,155 $5.51 Million
Q1 2021 May 13, 2021	BUY	$13.3 - $17.55 $185,402 - $244,647	13,940 Added 5.11%	286,577 $4.38 Million
Q4 2020 Feb 09, 2021	BUY	$12.08 - $17.46 $1.15 Million - $1.66 Million	95,325 Added 53.76%	272,637 $3.85 Million
Q3 2020 Nov 12, 2020	SELL	$13.62 - $17.66 $113,195 - $146,772	-8,311 Reduced 4.48%	177,312 $2.78 Million
Q2 2020 Aug 12, 2020	BUY	$13.04 - $23.23 $1.95 Million - $3.47 Million	149,591 Added 415.16%	185,623 $3.25 Million
Q1 2020 May 06, 2020	BUY	$11.52 - $26.46 $2,131 - $4,895	185 Added 0.52%	36,032 $529,000
Q4 2019 Feb 14, 2020	BUY	$15.24 - $25.09 $18,028 - $29,681	1,183 Added 3.41%	35,847 $899,000
Q3 2019 Nov 07, 2019	SELL	$14.91 - $25.01 $58,477 - $98,089	-3,922 Reduced 10.16%	34,664 $521,000
Q2 2019 Aug 12, 2019	BUY	$21.48 - $27.71 $270,819 - $349,367	12,608 Added 48.53%	38,586 $964,000
Q1 2019 May 14, 2019	BUY	$21.07 - $29.31 $58,953 - $82,009	2,798 Added 12.07%	25,978 $591,000
Q4 2018 Feb 11, 2019	BUY	$22.4 - $35.39 $165,020 - $260,718	7,367 Added 46.59%	23,180 $695,000
Q3 2018 Nov 09, 2018	BUY	$22.66 - $36.8 $358,322 - $581,918	15,813 New	15,813 $0

Others Institutions Holding CRNX

# of Institutions

240

Shares Held

79.5M

Call Options Held

23.3K

Put Options Held

44.3K

Vanguard Group Inc Valley Forge, PA

6.29M
Shares

$344 Million
0.01% of portfolio
Black Rock Inc. New York, NY

6.23M
Shares

$341 Million
0.01% of portfolio
Driehaus Capital Management LLC Chicago, IL

5.89M
Shares

$322 Million
2.95% of portfolio
Price T Rowe Associates Inc Baltimore, MD

4.94M
Shares

$271 Million
0.03% of portfolio
Wellington Management Group LLP Boston, MA

4.46M
Shares

$244 Million
0.04% of portfolio

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.94B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Account